

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
WO 2003/092669 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/165,  
31/196, A61P 27/02, 27/06

(21) International Application Number:  
PCT/US2003/011769

(22) International Filing Date: 16 April 2003 (16.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/377,429 3 May 2002 (03.05.2002) US

(71) Applicant (for all designated States except US): ALCON,  
INC. [CH/CH]; P.O. BOX 62, BOSCH 69, HUNENBERG,  
CH-6331 SWITZERLAND (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BINGAMAN,  
David P., [US/US]; 901 Meadow Hill Road, Ft. Worth,  
TX 76108 (US). KAPIN, Michael A., [US/US]; 3602  
Silkwood Trail, Arlington, TX 76016 (US). GAMACHE,  
Daniel A., [US/US]; 5610 Hunterwood Lane, Arlington,

TX 76017 (US). GRAFF, Gustav, [US/US]; 6500 County  
Road 809, Cleburne, TX 76031 (US). YANNI, John M.,  
[US/US]; 2821 Donnybrook Drive, Burleson, TX 76028  
(US).

(74) Agents: YEAGER, Sally S., et al.; R & D Counsel, Mail  
Code Q-148, 6201 South Freeway, Fort Worth, TX 76134  
(US).

(81) Designated States (national): AU, BR, CA, CN, JP, KR,  
MX, PL, US, ZA.

(84) Designated States (regional): European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

Published:


— with international search report

(88) Date of publication of the international search report:  
25 March 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISOR-  
DERS USING AMFENAC OR NEPAFENAC

Effect of Amfenac on VEGF-induced cell proliferation  
in Bovine Retinal Microvascular Endothelial Cells



[\*P < 0.001 vs. VEGF + vehicle (0.1% DMSO)]

(57) Abstract: The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vas-  
cular disorders.

WO 2003/092669 A3

Rec'd PST/PTO 14 OCT 2004

WO 03/092669 A2



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/11769

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/165 A61K31/196 A61P27/02 A61P27/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, PAJ, WPI Data, EMBASE, PASCAL, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/037929 A1 (GRAFF GUSTAV ET AL) 28 March 2002 (2002-03-28) column 2-3 example 1 claims 1-9	1-10
X,P	--- TAKAHASHI KYOICHI ET AL: "Topical nepafenac inhibits ocular neovascularization." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. UNITED STATES JAN 2003, vol. 44, no. 1, January 2003 (2003-01), pages 409-415, XP009013970 ISSN: 0146-0404 page 409 page 412-414 --- -/-	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 October 2003

Date of mailing of the international search report

17/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Domingues, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/11769

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>DATABASE BIOSIS 'Online!  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US; 2002  PENN J S ET AL: "Studies of the Effect and  Mechanism of Action of Topical Nepafenac  in a Rat Model of ROP."  Database accession no. PREV200300154861  XP002247860  abstract  &amp; ARVO ANNUAL MEETING ABSTRACT SEARCH AND  PROGRAM PLANNER,  vol. 2002, 2002, page Abstract No. 2741  Annual Meeting of the Association For  Research in Vision and Ophthalmology;Fort  Lauderdale, Florida, USA; May 05-10, 2002</p>	1-10
X,P	<p>DATABASE BIOSIS 'Online!  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US; 2002  BINGAMAN D P ET AL: "Topical Ocular  Delivery of Nepafenac Inhibits Preretinal  Neovascularization."  Database accession no. PREV200300165352  XP002247861  abstract  &amp; ARVO ANNUAL MEETING ABSTRACT SEARCH AND  PROGRAM PLANNER,  vol. 2002, 2002, page Abstract No. 3920  Annual Meeting of the Association For  Research in Vision and Ophthalmology;Fort  Lauderdale, Florida, USA; May 05-10, 2002</p>	1-10
Y	<p>KWAK N ET AL: "VEGF is major stimulator  in model of choroidal neovascularization."  INVESTIGATIVE OPHTHALMOLOGY &amp; VISUAL  SCIENCE. UNITED STATES SEP 2000,  vol. 41, no. 10, September 2000 (2000-09),  pages 3158-3164, XP009013972  ISSN: 0146-0404  page 3161 -page 3162</p>	1-10
Y	<p>WO 01 15744 A (BRIGHAM &amp; WOMENS HOSPITAL)  8 March 2001 (2001-03-08)  page 9  page 3</p>	1-10
A,P	<p>WO 02 078681 A (ALCON INC ;GRAFF GUSTAV  (US); HELLBERG MARK R (US); YANNI JOHN M  ()) 10 October 2002 (2002-10-10)  page 5  example 2</p>	1-10

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1 and 3 refer to vascular diseases defined by reference to a biological mechanism - vascular endothelial growth factor mediated vascular disorders. The claims cover all the conditions mediated by this mechanism, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such conditions. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely for the search term "vascular disorders" and for the diseases mentioned in claims 2 and 4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/11769

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/11769

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002037929	A1	28-03-2002	AU 8333701 A CA 2417282 A1 EP 1309323 A2 WO 0213804 A2	25-02-2002 21-02-2002 14-05-2003 21-02-2002
WO 0115744	A	08-03-2001	AU 7110300 A CA 2381926 A1 EP 1212101 A1 JP 2003508453 T WO 0115744 A1	26-03-2001 08-03-2001 12-06-2002 04-03-2003 08-03-2001
WO 02078681	A	10-10-2002	WO 02078681 A2 US 2002183376 A1	10-10-2002 05-12-2002